Healthcare Technology

credit / rates affecting interest expense

“Year Ended March 31, 2026 2025 Net income $ 4,969,961 $ 1,952,895 Impairment of contract assets 664,217 - Stock-based compensation 770,220 - Non-GAAP Net Income 6,404,398 1,952,895 Depreciation and amortization 369,249 545,709 Other income - (1,831 ) Income tax benefit/(provision) (1,483,603 ) 1,294,312 Deferred tax liability / (asset) - 40,550 Interest expense 475,071 329,892 Foreign exchange gain/(loss) (246,874 ) (101,383 ) Interest income (125,185 ) (42,688 ) Adjusted EBITDA $ 5,393,056 $ 4,017,456 In the fiscal year ended March 31, 2026, our adjusted EBITDA increased by approximately $1,375,601, or 34.2%, compared to the prior fiscal year, primarily due to revenue growth of approximately 18% combined with disciplined operating expense management, partially offset by increased operating expenses related to public company costs and sales organization expansion.”

FATN 10-K

restructuring

“Year Ended March 31, 2026 2025 Net income attributable to stockholders $ 4,969,961 $ 1,966,408 Impairment of contract assets 664,217 - Stock-based compensation 770,220 - Non-GAAP Net Income 6,404,398 1,952,895 Weighted-average shares of common stock outstanding - basic 13,882,787 12,858,852 Effect of dilutive securities 123,605 - Weighted-average shares of common stock outstanding - diluted 14,006,392 12,858,852 Non-GAAP Earnings per share - basic $ 0.46 $ 0.15 Non-GAAP Earnings per share - diluted $ 0.46 $ 0.15 In the fiscal year ended March 31, 2026, our Non-GAAP Net Income increased by approximately $4,451,503, or 228%, compared to the prior fiscal year.”

FATN 10-K

legal / regulatory

“This growth is being driven by expanding cloud migration, the proliferation of Internet of Things (IoT) and edge-computing devices, increasingly complex cyber-threat landscapes and regulatory requirements, and an ongoing shift in enterprise spending toward software-defined and integrated security platforms.”

FATN 10-Q